The CEO of Medical Marijuana, Inc., Blake Schroeder, recently penned an article for Nasdaq News that offers a business analysis on the prospects for federal cannabis legalisation in the United States. The “Company” has introduced the first cannabis-derived nutraceutical products, brands, and supply chain in the history of publicly traded cannabis companies in the United States.
The essay by Blake, “How Using the CBD Marketplace Can Set a Strong Stage for U.S. Cannabis”, describes how the non-psychoactive hemp CBD industry gives a unique chance to build a client base. It also points out the need to establish a foundation for selling psychoactive marijuana products, such as tetrahydrocannabinol (THC), if it becomes legal at the federal level.
In terms of regulatory, testing, banking, legal, and other business-related issues, this article demonstrates how the THC market, which is currently only legal in a few states, might benefit from the knowledge gained by the CBD industry prior to the passing of the 2018 Farm Bill.
He claims that companies looking to enter this industry may lay a solid foundation for a THC market that is federally authorised and for certain products. Blake also talks about how important international product pipelines are. These pipelines have the potential and challenge to give people all over the world unrestricted access to cannabis products and to reach new, less-developed areas that may change their laws about selling cannabis in the future.
CEO Blake Schroeder from Medical Marijuana, Inc. said, “I am very proud of the hard work our company has done to create a legitimate and legal non-psychoactive cannabis marketplace that we have today and am excited to see that replicated in the THC market once our federal legislation changes,”
Once federally legalized, we feel we are well-positioned to take advantage of that opportunity.” As laws around the world change for the better, we will be able to benefit from our worldwide infrastructure. “
Medical Marijuana, Inc.: A Brief Overview.
We pride ourselves on being a pioneering organization®.
Medical Marijuana Company (MJNA) has three distinct business units in the non-psychoactive cannabinoid space
- Kannaway® and HempMeds® led global portfolio of cannabinoid-based nutraceutical brands
- a pioneer in the sourcing of legal, non-psychoactive cannabis products from industrial hemp
- cannabinoid-based clinical research and botanical drug development led by its pharmaceutical investment companies and partner companies.
CBD manufacturer Medical Marijuana, Inc. has been recognized by CNBC as one of the best. Additionally, it was the first business to get historic import licenses for CBD products from Brazil, Mexico, Argentina, and Paraguay and is a major player in the international market development.
Clinical trials in Mexico and Brazil have proven the safety and usefulness of the company’s flagship product, Real Scientific Hemp Oil. Medical Marijuana, Inc.’s headquarters are located in San Diego, California.